Skip to main content

Impower-024 is a randomized drug trial for HIV prevention, open to cis men and trans women who have sex with partners who were assigned male at birth (AMAB). The main purpose of this study is to determine the safety and efficacy of an HIV drug called islatravir used for Pre-Exposure Prophylaxis (PrEP). Islatravir is in a new class of HIV medications and is taken by mouth once a month.

In this study, participants will receive either monthly islatravir and a daily placebo for Descovy, or a monthly placebo and daily Descovy. All participants will in this way receive PrEP; two participants will receive monthly islatravir for every one participant who will receive Descovy.

The study is recruiting in the U.S. and abroad, and UNC is one of at least 15 international sites. Cis men and trans women 16 years and older are eligible to enroll if they are confirmed HIV-negative, have had anal sex with a partner AMAB within the last month, and meet at least one of a list of criteria about sexual behaviors. Number:  NCT04652700